Fox Chase Cancer Center, part of the Temple University Health System in Philadelphia, has received a grant for $673,000 from the U.S. Department of Defense to develop an improved method for screening for lung cancer.
Martin J. Edelman, MD, chair of the department of Hematology/Oncology at Fox Chance Cancer Center, and colleagues will work on research focused on using cancer associated macrophage-like (CAML) cells to determine if a small or indeterminate lung nodule is malignant or benign.
“Low-dose CT scans have the potential to dramatically lower lung cancer death rates, but there are too many indeterminate cases and false positives,” Edelman said in a prepared statement. “We are working on a simple, minimally invasive test for CAMLs, which will serve as second-level screening for patients whose lung scans are inconclusive.”
The team’s study is set to take place at both Fox Chase Cancer Center and the Philadelphia VA.
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.